A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)

Inclusion Criteria:

• Has a histologically confirmed diagnosis of unresectable Stage IV (per AmericanJoint Committee on Cancer [AJCC], 8th Edition) RCC with clear-cell component

• Has had disease progression on or after having received at least 2 systemictreatments for unresectable Stage IV RCC with prior anti-programmed cell death 1ligand 1 (PD-1/L1) and a vascular endothelial growth factor-tyrosine kinaseinhibitor (VEGF-TKI) in sequence or in combination

• Has measurable disease per RECIST 1.1 as assessed by the investigator and verifiedby blinded independent central review (BICR)

• Has recovered from all AEs due to previous therapies

Exclusion Criteria:

• Has hypoxia, requires intermittent supplemental oxygen, or requires chronicsupplemental oxygen

• Has a known additional malignancy that is progressing or has required activetreatment within the past 3 years

• Has known central nervous system (CNS) metastases and/or carcinomatous meningitis

• Has clinically significant cardiac disease

• Has moderate to severe hepatic impairment

• Has a known history of human immunodeficiency virus (HIV) infection

• Has a history of hepatitis B (HBV) or known active hepatitis C (HCV) infection

• Has received prior treatment of belzutifan or palbociclib

• Has received prior radiotherapy ≤2 weeks prior to first dose of study intervention.Participants must have recovered from all radiation-related toxicities and notrequire corticosteroids

• Has had major surgery ≤3 weeks prior to first dose of study intervention

• Has received colony-stimulating factors (eg, granulocyte colony-stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor [GM-CSF], or recombinanterythropoietin [EPO]) ≤28 days prior to the first dose of study intervention